Mounjaro®, dehydration and the kidneys

What the warning describes

Section 5.5 of the US label is titled Acute Kidney Injury Due to Volume Depletion. Volume depletion means the body has lost more fluid than it has taken in. Since approval, there have been reports of acute kidney injury, a few serious enough to need haemodialysis, among users of Mounjaro® and other GLP-1 receptor agonists; in most, stomach and bowel reactions had caused dehydration first ^[1]. Section 6.2 lists acute kidney failure, and worsening of chronic kidney failure, among reports without a frequency ^[1].

Canada’s monograph adds that some of these events were reported in people without known kidney disease, and asks for kidney monitoring when starting or increasing the dose in people with severe stomach reactions ^[4]. Its patient information rates dehydration leading to sudden kidney failure as rare ^[4]. The European information frames the same chain: nausea, vomiting and diarrhoea can cause dehydration, which could worsen kidney function, including acute renal failure ^[3].

The reactions that can lead there

The warning points to nausea, vomiting and diarrhea. Their rates in the US adult placebo-controlled pool are below, with the section 5.6 figure for stomach and bowel reactions classed as severe ^[1].

Why starts and dose increases are singled out

The monitoring advice names two moments, starting Mounjaro® and raising the dose, which match the label’s observation that most nausea, vomiting and diarrhea came during dose escalation and became less common later ^[1]. The schedule raises the dose in 2.5 mg steps no more often than every four weeks, partly to reduce these reactions ^[1].

Some groups vomited more: children aged 10 and older (16% on 5 mg and 12% on 10 mg, against 3% on placebo) and adults in the SURPASS-CVOT heart trial (12%) ^[1]. In European weight-management trials, nausea and diarrhea were more frequent than in the diabetes trials ^[3]. The European information also asks for particular attention to dehydration in older people ^[3].

If your kidneys are already affected

The US label says no dose adjustment is recommended for kidney impairment, because tirzepatide levels in the body were unchanged, even in end-stage kidney disease, both in a single-dose study and in people with type 2 diabetes and kidney impairment in clinical trials ^[1]. It asks for kidney function to be monitored when Mounjaro® is started or increased in people with kidney impairment who report severe stomach or bowel reactions ^[1].

Europe adds that experience in severe impairment and end-stage disease is limited and calls for caution, and Canada does not recommend Mounjaro® in end-stage kidney disease ^[3][4]. People with reduced kidney function were part of the trials: in Canada’s trial population, 39.5% had mild and 7.3% moderate impairment, but only 0.2% severe impairment ^[4].

What kidney analyses of the trials found

Several analyses looked at kidney markers over time. In a manufacturer-funded post hoc analysis of SURPASS-4, an open-label trial in adults with type 2 diabetes at high risk of heart disease, estimated kidney function (eGFR) fell more slowly on tirzepatide than on insulin glargine, by 1.4 against 3.6 units a year, and urine albumin did not rise as it did on glargine ^[5]. In a pre-specified exploratory analysis of SURPASS-CVOT, a composite of major kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide over a median of four years ^[6].

A 2025 meta-analysis of 15 randomised trials found tirzepatide reduced urine albumin compared with placebo, left eGFR similar to comparators, and did not raise the risk of acute kidney injury, urinary infections or kidney stones ^[7]. These results are about kidney markers over time and are not the same as the dehydration warning; none of the three labels lists kidney protection as an approved use ^[1][3][4].

What a reporting study adds

A study of the US FDA adverse event reporting database compared acute kidney injury reports for tirzepatide and semaglutide. Kidney injury appeared in 0.47% of tirzepatide reports against 1.07% of semaglutide reports, a lower relative reporting frequency for tirzepatide ^[8]. The authors note that such data cannot confirm cause and are open to reporting bias, and they still advise attention to hydration and kidney monitoring when these medicines are started ^[8].

Signs of dehydration and kidney trouble

Canada’s patient information describes dehydration that can cause sudden kidney failure as dark yellow, strong-smelling urine, feeling extremely thirsty, and feeling dizzy or light-headed ^[4]. MedlinePlus adds a dry or sticky mouth, passing little urine, headache and muscle cramps for milder dehydration, and very dark or no urine, confusion, a racing heart and fast breathing for severe dehydration ^[10].

For acute kidney failure itself, MedlinePlus lists little or no urine, swelling of the legs, ankles or feet, tiredness, shortness of breath, nausea and changes in mental state among possible symptoms ^[9]. It also names other causes, including anti-inflammatory painkillers, certain antibiotics and blood pressure medicines, contrast dye, serious illness and a blocked urinary tract ^[9]. If you take any of these, mention them to your prescriber.

What the labels ask of patients

• Drink fluids: the Medication Guide says this helps reduce the chance of dehydration, and the European leaflet stresses it when starting treatment ^[2][3].
• Report nausea, vomiting or diarrhea that does not go away right away; section 17 asks clinicians to tell patients to do this promptly ^[1][2].
• Take precautions against losing too much fluid, as section 17 puts it; what that means for you, especially with kidney or heart disease or fluid limits, is a question for your clinician ^[1].
• Mention known kidney disease before starting, so the monitoring the label describes can be planned ^[1].

Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.